A synthetic lethal relationship between PLK4 inhibition and TRIM37 overexpression in cancers with amplifications or gains of the chromosomal region 17q23, commonly observed in breast cancer and neuroblastoma, has brought PLK4 inhibitors into the spotlight as potential therapeutics. The gene discussed is PLK4; the disease is breast cancer.